

Sub C3

5. (Amended) [A] The compound [according to any of claims 1 to 3] of claim 1, wherein x is 1 or 2, and R¹ is selected from the group consisting of hydroxy, C₁ to C₉ alkoxy (optionally substituted by halo), C₁ to C₉ cycloalkylalkoxy (wherein the cycloalkyl group is optionally substituted by C₁ to C₄ alkyl or halo, and the alkoxy group is optionally substituted by halo), arylalkoxy (wherein the aryl group is optionally substituted by C₁ to C₄ alkyl, C₁ to C₃ alkoxy or halo, and the alkoxy group is optionally substituted by halo) and C₁ to C₉ alkylamino wherein the alkyl group is optionally substituted by halo.


6. (Amended) [A] The compound [according to any preceding claim] of claim 1, wherein R³ is H, C₁ to C₇ alkyl or benzyl.

7. (Amended) [A] The compound [according to any preceding claim] of claim 1, wherein R⁵, R⁶ and R⁷ are independently selected from the group consisting of H, aryl(C₁ to C₃)alkyl and cycloalkyl(C₁ to C₃)alkyl, and are optionally substituted by halo.

8. (Amended) [A] The compound [according to any preceding claim] of claim 1, wherein Y is propylene, butylene, pentylene, hexylene, heptylene, octylene or nonylene.

9. (Amended) [A] The compound [according to any preceding claim] of claim 1, wherein m+n ≥ 3.

10. (Amended) [A] The compound [according to] of claim 8, wherein m+n ≥ 3, Z-R² is




and R⁵ is benzyl or halobenzyl.

Please cancel claim 11 without prejudice.

12. (Amended) A compound which is degraded *in vivo* to yield [a] the compound [according to any] of [claims] claim 1 [to 10].

A2
13. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of [a] the compound [according to any] of [claims] claim 1 [to 10], and a physiologically acceptable diluent or carrier.

28. (Amended) [The use of an H₃ receptor ligand in the manufacture of a medicament for] A method of modifying H₃ receptor activity in a patient, which comprises administering to a patient in need of a modification a therapeutically effective amount of H₃ receptor ligand or a pharmaceutically acceptable salt thereof, said H₃ receptor ligand being a compound of the formula



AB
wherein

A is (CH₂)_m, m being from 1 to 3;

B is (CH₂)_n, n being from 1 to 3;

x is from 0 to 2;

R¹ is C₁ to C₁₀ hydrocarbyl, in which up to 2 carbon atoms may be replaced by O, S or N, and up to 2 hydrogen atoms may be replaced by halogen;

R² is H or C₁ to C₁₅ hydrocarbyl, in which up to 3 carbon atoms may be replaced by O, S or N, and up to 3 hydrogen atoms may be replaced by halogen;






R³ is absent when -Y-Z-R² is attached to W, or is H or C₁ to C₇ hydrocarbyl when -Y-Z-R² is not attached to W;

W is nitrogen;


X is $-\text{CH}_2-$, $-\text{O}-$ or $-\text{NR}^4-$, R^4 being H or C₁ to C₃ alkyl;

Y replaces a hydrogen atom on any of A, B, W and X, and is C₂ to C₁₀ alkylene, in which one non-terminal carbon atom may be replaced by O; and

Z is



or



A3

wherein R⁵, R⁶ and R⁷ are independently H or C₁ to C₁₅ hydrocarbyl, in which up to 3 carbon atoms may be replaced by O or N, and up to 3 hydrogen atoms may be replaced by halogen, and Q is H or methyl, or Q is linked to R⁵ or R⁷ to form a five-membered ring or Q is linked to R² to form a six-membered ring.